A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.
There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals and humans, researchers said.
The team developed an innovative approach to use mechanogenetics—a field of science that focuses on how physical forces and changes in the mechanical properties of cells and tissues influence gene expression—for the remote control of gene and cell activations. Researchers used ultrasound to mechanically perturb T cells, and then converted the mechanical signals into genetic control of cells.
In this study, researchers show how their remote-controlled mechanogenetics system can be used to engineer chimeric antigen receptor (CAR)-expressing T cells that can target and kill cancer cells. The engineered CAR-T cells have mechano-sensors and genetic transducing modules that can be remotely activated by ultrasound via microbubble amplification.
“CAR-T cell therapy is becoming a paradigm-shifting therapeutic approach for cancer treatment,” said bioengineering professor Peter Yingxiao Wang at the University of California San Diego. “However, major challenges remain before CAR-based immunotherapy can become widely adopted. For instance, the non-specific targeting of CAR-T cells against nonmalignant tissues can be life-threatening. This work could ultimately lead to an unprecedented precision and efficiency in CAR-T cell immunotherapy against solid tumors, while minimizing off-tumor toxicities.”
The team brings together the laboratories of professors Wang and Shu Chien, both bioengineering professors at the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego, in collaboration with professors Kirk Shung of the University of Southern California and Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. Researchers present their findings in the Jan. 15 issue of the Proceedings of the National Academy of Sciences, with UC San Diego Ph.D. candidate Yijia Pan as the first author.
Researchers found that microbubbles conjugated to streptavidin can be coupled to the surface of a cell, where mechanosensitive Piezo1 ion channels are expressed. Upon exposure to ultrasound waves, microbubbles vibrate and mechanically stimulate Piezo1 ion channels to let calcium ions inside the cell. This triggers downstream pathways, including calcineurin activation, NFAT dephoshorylation and translocation into the nucleus. The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
The Latest on: CAR-T cell therapy
T cell engineering breakthrough sidesteps need for viruses in gene-editing
on July 11, 2018 at 11:40 am
These limitations, which could potentially lead to serious side effects, have been cause for concern in both gene therapy and cell therapies such as CAR-T-based immunotherapy. "There has been thirty y... […]
Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma
on July 10, 2018 at 2:56 pm
Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL). At the 2018 Europ... […]
CAR T-Cell Therapy Offers Hope in DLBCL
on July 10, 2018 at 9:29 am
Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann ... […]
Rubius Therapeutics to invest $155M, hire 160 workers for cell therapy plant
on July 10, 2018 at 8:45 am
Enthusiasm in the immuno-oncology therapies being developed by Rubius Therapeutics has allowed the biotech to quickly raise $220 million, a large chunk of which it will invest in a cell therapy manufa... […]
Med Beat: VCU offers new way to help lymphoma patients' immune system kill cancer cells
on July 5, 2018 at 9:24 am
The Virginia Commonwealth University Massey Cancer Center is the first in Virginia to offer patients with certain types of lymphoma a new therapy that genetically alters their own immune system to sea... […]
CAR T-cell Therapy in Lymphocytic Leukemia| A Pipeline Analysis Report 2018| Technavio
on July 5, 2018 at 9:23 am
LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the CAR T-cell therapy in lymphocytic leukemia market. The report includes a detailed analysis of the pipeline ... […]
Fratricide-resistant CAR T-cell therapy may have utility in acute lymphoblastic leukemia
on July 5, 2018 at 5:08 am
Patients with relapsed or refractory acute lymphoblastic leukemia may benefit from a novel fratricide-resistant chimeric antigen receptor T-cell therapy approach, according to study results. Matthew L ... […]
ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma
on July 3, 2018 at 3:03 pm
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ... […]
New cell-based immunotherapy treatments give hope to cancer patients
on July 2, 2018 at 7:40 am
Chimeric antigen receptor (CAR) T-cell therapy is one of the most exciting and most promising cell-based immunotherapies and has just recently been approved by the FDA to treat certain types of relaps... […]
First Two CAR T-Cell Therapies Get Thumbs Up From EMA Panel
on June 29, 2018 at 2:40 pm
The main safety concerns with CAR T-cell therapy (CAR-T) are cytokine release syndrome (CRS), which is a systemic response involving high fever and flu-like symptoms, and neurologic toxicities. Both c... […]
via Google News and Bing News